Antihypertensive therapy in the prevention of stroke. What, when and for whom?

Drugs

Volumn 58, Issue 4, 1999, Pages 663-674

  Fotherby, Martin D ^a   Panayiotou, Barnabas ^b  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b MANOR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; NITRENDIPINE; THIAZIDE DIURETIC AGENT;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; CLINICAL TRIAL; DIABETES MELLITUS; DYSPHAGIA; HEART FAILURE; HUMAN; PRIMARY PREVENTION; REVIEW; RISK; SECONDARY PREVENTION; STROKE; SYSTOLIC HYPERTENSION;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYPERTENSION; RECURRENCE;

ANGINA;

EID: 0032758590     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958040-00006     Document Type: Review

References (72)

1. 1. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens 1996; 14 Suppl. 6: s39-46
2. 2. Neilsen WB, Lindenstrom E, Vestvo J, et al. Is diastotic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle aged and elderly? Am J Hypertens 1997; 10: 634-9
3. 3. Sacco RL, Chair MS, Benjamin EJ, et al. Risk factors. Stroke 1997; 28: 1507-17
4. 4. Philips SJ, Withsnant JP. Hypertension and the brain. Arch Intern Med 1992; 152: 938-45
5. 5. Thrift AG, MacNeal JJ, Forbes A, et al. Risk factors for cerebral haemorrhage in the era of well controlled hypertension. Stroke 1996; 27: 2020-5
6. 6. Bland AD, Waite MA. von Willenbrand factor and soluble e-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 1996; 7: 143-7
7. 7. Lip GYH, Blan AD, Zarifis J, et al. Soluble adhesion molecule p-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens 1995; 13: 1674-8
8. 8. Fotherby M, Williams J, Forster L, et al. von Willebrand factor and monocyte adhesion are associated with pulse pressure and e-selectin with mean arterial pressure [abstract]. Age Ageing 1999; 28 (Suppl.): 20
9. 9. Lottermoser K, Weisser B, Hertfelder HJ, et al. Antihypertensive drug treatment and fibrinolytic function. Am J Hypertension 1998; 11: 378-84
10. 10. Bikkina M, Levi D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA 1994; 272: 33-6
11. 11. Gottdiener JS, Reda DJ, Massie BM, et al. The effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-14
12. 12. Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertension 1998; 16 Suppl. 6: S29-34
13. 13. Gottdiener JS, Reda DJ, Williams WW, et al. Effect of single drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1998; 98: 140-8
14. 14. MacMahon S, Peto R, Kupler J, et al. Blood pressure stroke and coronary heart disease. Part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
15. 15. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Older Patients with hypertension (STOP - Hypertension). Lancet 1991; 338: 1281-5
16. 16. Coope J, Warrender TS. Randomised trial of the treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-51
17. 17. Amery A, Birkenhager W, Brixco P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349-54
18. 18. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
19. 19. Management Committee. Treatment of mild hypertension in the elderly; a study initiated and administered by the National Heart Foundation of Australia. Med J Aust 1981; 2: 398-402
20. 20. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Programme (SHEP). JAMA 1991; 265: 3255-64
21. 21. Staessen JA, Fagard R, Thijs L, et al. Randomised double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64
22. 22. Liu L, Wang G, Gong L, et al., for the Systolic Hypertension in China Collaborative Group, Comparison of active treatment and placeho in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823-9
23. 23. Gucyffier F, Bulpitt C, Boissel J-P, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDIANA Group. Lancet 1999; 353: 793-6
24. 24. Curb JD, Pressel SL, Kupler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92
25. 25. Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes; UKPDS 38. UK Prospective Diabetes Study Group [published eratum appears in BMJ 1999; 318: 29]. BMJ 1998; 317: 703-13
26. 26. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-8
27. 27. Core Services Committee. Guidelines for the management of mildly raised blood pressure in New Zealand. Wellington, New Zealand: Ministry of Health, 1995
28. 28. Fotherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients. J Hypertens 1992; 10: 1403-8
29. 29. Fotherby MD, Potter JF. Effects of moderate sodium restriction on clinic and 24-hour ambulatory blood pressure in elderly hypertensive subjects. J Hypertens 1993; 11: 657-63
30. 30. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-45
31. 31. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-7
32. 32. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertension 1996; 14: 1237-45
33. 33. Joint National Committee on the Prevention and Detection, Evaluation and Treatment of High Blood Pressure. The 6th report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2430-46
34. 34. Frischman WH, Furburg CD, Freedwald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310: 830-7
35. 35. Borhani NO, Mercuri M, Berani PA, et al. Final outcome results of the Multicentre Ispradipine Diuretic Atherosclerosis Study (MIDAS). A randomised control trial. JAMA 1996; 276: 785-91
36. 36. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for re-evaluation? Circulation 1995; 92: 1079-82
37. 37. Estacio RO, Jeffers B, Hiatt W, et al. The effect of Nizoldipine as compared with Enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52
38. 38. Pahor M, Psaty BM, Ferberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 352: 689-90
39. 39. Hanson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
40. 40. Jorgensen HS, Nakayama H, Reith J, et al. Stroke recurrence: predictors, severity and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48: 891-5
41. 41. Merit JV, Adams GF. Comparison of mortality rates in elderly hypertensive and normotensive hemiplegic patients. BMJ 1966; 2: 802-5
42. 42. Meissner I, Whistnant JP, Garraway WM. Hypertension management and stroke recurrence in the community (Rochester, Minnesota, 1950-1979). Stroke 1988; 19: 459-63
43. 43. Johnston JH, Beevers DG, Titterington BM. The importance of good blood pressure control in the prevention of stroke recurrence in hypertensive patients. Postgrad Med J 1981; 57: 690-3
44. 44. Iric K, Yamagucuchi T, Minematsu K, et al. The J-curve phenomenon stroke recurrence. Stroke 1993; 24: 1844-9
45. 45. Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ 1996; 313: 147
46. 46. Carter AB. Hypotensive therapy and stroke survivors. Lancet 1970; 1: 485-9
47. 47. Hypertension Stroke Co-operative Study Group Effect of antihypertensive treatment and stroke recurrence. JAMA 1974; 229: 409-18
48. 48. Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischaemic attack on non-disabling ischaemic stroke. Stroke 1993; 24: 543-8
49. 49. Ericsson S, Olofsson BO, Wester PO, for the TEST Study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21-5
50. 50. PATS Collaborating Group. Post stroke antihypertensive treatment study: a preliminary result. Chin Med J 1995; 108: 710-7
51. 51. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28: 2557-62
52. 52. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996; 14 Suppl. 2: s41-6
53. 53. Philips SJ, Sandercock P, Slatter J. U-shaped relationship between systolic pressure and early death after acute ischaemic stroke [abstract]. Can J Neurol Sci 1995; 22 (1): s44
54. 54. Robinson TG, Waddington A, Ward-Close SJ, et al. The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997; 7: 264-72
55. 55. Strandgaard S. Cerebral ischaemia caused by overzealous blood pressure lowering. Dim Med Bull 1987; 34 Suppl. 1: 5-7
56. 56. Evidente V, Yagnik P. Blood pressure management in acute stroke [abstract]. Am Acad Neurol 1996; 46 (2 Suppl. 1): A256
57. 57. Strangaard S, Paulson OB. Cerebral autoregulation. Stroke 1984; 15: 413-6
58. 58. Britton M, Carlsson A, deFaire U. Blood pressure course in patients with acute stroke and matched controls. Stroke 1986; 17: 861-4
59. 59. Harper G, Fotherby MD, Panayiotou BN, et al. The changes in blood pressure after acute stroke: abolishing the while coat effect with 24-hour ambulatory monitoring. J Intern Med 1994; 325: 343-6
60. 60. Barer DH, Cruickshank JM, Ebrahim SB, et al. Low dose β-blockade in acute stroke (BEST) trial: an evaluation. BMJ 1988; 296: 737-41
61. 61. Wahlgren NG, MacMahon OG, De Keyser J, et al., for the INWEST Study Group, Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994; 4: 204-10
62. 62. Squire IB, Lees KR, Pryse-Philips W, et al. Lifarizine Study Group: a pilot safety study. Cerebrovasc Dis 1996; 6: 156-60
63. 63. Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS n-PA Stroke Trial. Stroke 1998; 29: 1504-9
64. 64. Waldemar G, Vorstrup S, Anderson AR, et al. Angiotensin converting enzyme inhibition and lesional cerebral blood flow in acute stroke. J Cardiovasc Pharmacol 1989; 14: 722-9
65. 65. Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischaemic stroke. Stroke 1997; 28: 580-3
66. 66. Lisk DR, Grotta JC, Lamki L. Should hypertension be treated after acute stroke? A randomised controlled trial using single photon emission computed tomography. Arch Neurol 1993; 50: 855-62
67. 67. Teitlbaum JS. Management of blood pressure in acute neurological illnesses. Neurologist 1996; 2: 196-206
68. 68. Tietjen CS, Hurn PD, Ulatowski JA, et al. Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Crit Care Med 1996; 24: 311-22
69. 69. Evans SN, Ahmed U, Fotherby MD. Effect of antihypertensive therapy on blood pressure after stroke [abstract]. Cerebrovasc Dis 1998; 8 Suppl. 4: 32
70. 70. Panayiotou B, Reid I, Fotherby MD, et al. Orthostatic haemodynamic responses in acute stroke. Postgrad Med J 1999; 75: 213-8
71. 71. Fotherby MD, Harper G, Potter JF. General practitioners management of hypertension in the elderly. BMJ 1992; 305: 705-2
72. 72. Lavin P. Management of hypertension in patients with acute stroke. Arch Int Med 1986; 146: 66-8